临床荟萃 ›› 2023, Vol. 38 ›› Issue (9): 838-844.doi: 10.3969/j.issn.1004-583X.2023.09.012
王鑫1, 张展1, 刘铎1, 谢萍2(
)
收稿日期:2023-07-06
出版日期:2023-09-20
发布日期:2023-11-21
通讯作者:
谢萍,Email:
Received:2023-07-06
Online:2023-09-20
Published:2023-11-21
摘要：
本文以肺动脉高压(pulmonary arterial hypertension,PAH)背景为基础,对缺铁与PAH的相关性进行阐述,并评估补铁在PAH治疗中的作用。部分PAH患者存在铁缺乏,缺铁与运动能力降低、死亡率升高有关。缺铁与PAH的发病机制相互交联,补铁可能会成为其治疗的新方法。通过检索文献以确定关于PAH补铁的所有可用证据。有限的证据表明,补充铁可降低肺动脉压力和提高活动耐力。因此,有必要对有良好生物利用度的口服铁或静脉铁进行更大规模的随机对照研究,以探讨补铁对PAH的潜在效用。
中图分类号:
王鑫, 张展, 刘铎, 谢萍. 铁缺乏与肺动脉高压相关性的研究进展[J]. 临床荟萃, 2023, 38(9): 838-844.
图1 PAH发生机制
| [1] |
Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: A review[J]. JAMA, 2022, 327(14): 1379-1391.
doi: 10.1001/jama.2022.4402 pmid: 35412560 |
| [2] |
Quatredeniers M, Mendes-ferreira P, Santos-ribeiro D, et al. Iron deficiency in pulmonary arterial hypertension: A deep dive into the mechanisms[J]. Cells, 2021, 10(2):477.
doi: 10.3390/cells10020477 URL |
| [3] |
Kramer T, Wissmüller M, Natsina K, et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: A long-term study[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1501-1512.
doi: 10.1002/jcsm.12764 pmid: 34498427 |
| [4] |
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1): 2200879.
doi: 10.1183/13993003.00879-2022 URL |
| [5] |
Lan M, Wu S, Fernandes TM. Iron deficiency and pulmonary arterial hypertension[J]. Nutr Clin Pract, 2022, 37(5): 1059-1073.
doi: 10.1002/ncp.v37.5 URL |
| [6] |
Shah AJ, Beckmann T, Vorla M, et al. New drugs and therapies in pulmonary arterial hypertension[J]. Int J Mol Sci, 2023, 24(6):5850.
doi: 10.3390/ijms24065850 URL |
| [7] |
Ricci A, DI Betto G, Bergamini E, et al. Iron metabolism in the disorders of heme biosynthesis[J]. Metabolites, 2022, 12(9):819.
doi: 10.3390/metabo12090819 URL |
| [8] |
Ottolenghi S, Zulueta A, Caretti A. Iron and sphingolipids as common players of (mal)adaptation to hypoxia in pulmonary diseases[J]. Int J Mol Sci, 2020, 21(1):307.
doi: 10.3390/ijms21010307 URL |
| [9] |
Di PA, Tortora C, Argenziano M, et al. Emerging roles of the iron chelators in inflammation[J]. Int J Mol Sci, 2022, 23(14):7977.
doi: 10.3390/ijms23147977 URL |
| [10] |
Sonnweber T, Pizzini A, Tancevski I, et al. Anaemia, iron homeostasis and pulmonary hypertension: A review[J]. Intern Emerg Med, 2020, 15(4): 573-585.
doi: 10.1007/s11739-020-02288-1 pmid: 32040829 |
| [11] | 宋丽丽. 铁稳态对肺动脉高压影响的研究进展[J]. 河北医药, 2022, 44(15): 2364-2368, 2374. |
| [12] |
Smith TG, Talbot NP, Privat C, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: Two randomized controlled trials[J]. JAMA, 2009, 302(13): 1444-1450.
doi: 10.1001/jama.2009.1404 pmid: 19809026 |
| [13] |
Spiekerkoetter E, Kawut SM, De Jesus PVA. New and emerging therapies for pulmonary arterial hypertension[J]. Annu Rev Med, 2019, 70: 45-59.
doi: 10.1146/annurev-med-041717-085955 pmid: 30216732 |
| [14] |
Mansueto G, Di NM, Campobasso CP, et al. Pulmonary arterial hypertension (PAH) from autopsy study: T-cells, B-cells and mastocytes detection as morphological evidence of immunologically mediated pathogenesis[J]. Pathol Res Pract, 2021, 225: 153552.
doi: 10.1016/j.prp.2021.153552 URL |
| [15] |
Evans CE, Cober ND, Dai Z, et al. Endothelial cells in the pathogenesis of pulmonary arterial hypertension[J]. Eur Respir J, 2021, 58(3): 2003957.
doi: 10.1183/13993003.03957-2020 URL |
| [16] |
Niihori M, Eccles CA, Kurdyukov S, et al. Rats with a human mutation of NFU1 develop pulmonary hypertension[J]. Am J Respir Cell Mol Biol, 2020, 62(2): 231-242.
doi: 10.1165/rcmb.2019-0065OC URL |
| [17] |
Chai T, Qiu C, Xian Z, et al. A narrative review of research advances in hypoxic pulmonary hypertension[J]. Ann Transl Med, 2022, 10(4): 230.
doi: 10.21037/atm-22-259 pmid: 35280399 |
| [18] |
Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding[J]. J Physiol, 2021, 599(6): 1745-1757.
doi: 10.1113/tjp.v599.6 URL |
| [19] |
Deng L, Han X, Wang Z, et al. The landscape of noncoding RNA in pulmonary hypertension[J]. Biomolecules, 2022, 12(6):796.
doi: 10.3390/biom12060796 URL |
| [20] | Zou HX, Qiu BQ, Lai SQ, et al. Iron metabolism and idiopathic pulmonary arterial hypertension: new insights from bioinformatic analysis[J]. Biomed Res Int, 2021, 2021: 5669412. |
| [21] |
Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer[J]. Mol Cancer, 2020, 19(1): 43.
doi: 10.1186/s12943-020-01168-8 pmid: 32106859 |
| [22] |
Tsai YM, Wu KL, Chang YY, et al. Loss of miR-145-5p causes ceruloplasmin interference with PHD-iron axis and HIF-2α stabilization in lung adenocarcinoma-mediated angiogenesis[J]. Int J Mol Sci, 2020, 21(14):5081.
doi: 10.3390/ijms21145081 URL |
| [23] |
Nemeth E, Ganz T. Hepcidin-ferroportin interaction controls systemic iron homeostasis[J]. Int J Mol Sci, 2021, 22(12):6493.
doi: 10.3390/ijms22126493 URL |
| [24] |
Meier JK, Schnetz M, Beck S, et al. Iron-bound lipocalin-2 protects renal cell carcinoma from ferroptosis[J]. Metabolites, 2021, 11(5):329.
doi: 10.3390/metabo11050329 URL |
| [25] |
Nishizawa H, Matsumoto M, Shindo T, et al. Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1[J]. J Biol Chem, 2020, 295(1): 69-82.
doi: 10.1074/jbc.RA119.009548 pmid: 31740582 |
| [26] |
Gao Q, Zhang G, Zheng Y, et al. SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC[J]. Cell Death Differ, 2020, 27(3): 1086-1104.
doi: 10.1038/s41418-019-0399-1 pmid: 31367013 |
| [27] |
Xie Q, Guo H, He P, et al. Tspan5 promotes epithelial-mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating notch signalling[J]. Mol Oncol, 2021, 15(11): 3184-3202.
doi: 10.1002/1878-0261.12980 pmid: 33955149 |
| [28] | Anderson RA, Schwalbach KT, Mui SR, et al. Zebrafish models of skeletal dysplasia induced by cholesterol biosynthesis deficiency[J]. Dis Model Mech, 2020, 13(6): 042549. |
| [29] |
Xu G, Li X, Zhu Z, et al. Iron overload induces apoptosis and cytoprotective autophagy regulated by ROS generation in mc3t3-e1 Cells[J]. Biol Trace Elem Res, 2021, 199(10): 3781-3792.
doi: 10.1007/s12011-020-02508-x pmid: 33405076 |
| [30] |
Boucly A, Savale L, Jaïs X, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2021, 204(7): 842-854.
doi: 10.1164/rccm.202009-3698OC URL |
| [31] |
Jin Q, Guan L, Pan W, et al. Initial triple combination therapy for intermediate-and high-risk pulmonary arterial hypertension: Standard of care or still too soon to tell?[J]. Am J Respir Crit Care Med, 2021, 204(12): 1491-1492.
doi: 10.1164/rccm.202107-1622LE URL |
| [32] | López-vilella R, Lozano-edo S, Arenas MP, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction[J]. ESC Heart Fail, 2022, 9(1): 133-145. |
| [33] |
Saluja P, Gautam N, Amisha F, et al. Influence of iron deficiency on clinical and haemodynamic parameters in pulmonary arterial hypertension cohorts[J]. Heart Lung Circ, 2022, 31(12): 1594-1603.
doi: 10.1016/j.hlc.2022.09.001 pmid: 36402703 |
| [34] |
Pasricha SR, Tye-din J, Muckenthaler MU, et al. Iron deficiency[J]. Lancet, 2021, 397(10270): 233-248.
doi: 10.1016/S0140-6736(20)32594-0 URL |
| [35] |
Culeddu G, Su L, Cheng Y, et al. Novel oral iron therapy for iron deficiency anaemia: how to value safety in a new drug?[J]. Br J Clin Pharmacol, 2022, 88(3): 1347-1357.
doi: 10.1111/bcp.v88.3 URL |
| [36] |
Alharbi AA, Alharbi AA, Bashen DS, et al. Evaluation of minimal optimal dose of intravenous ferric carboxymaltose for treatment of iron deficiency anemia and risk of transient hyperferritinemia[J]. J Blood Med, 2022, 13: 681-690.
doi: 10.2147/JBM.S374780 pmid: 36419736 |
| [37] |
Arici AM, Kumral Z, Gelal A, et al. Fatal anaphylactic reaction due to ferric carboxymaltose: A case report[J]. Anatol J Cardiol, 2020, 24(2): 115-117.
doi: 10.14744/AnatolJCardiol.2020.38996 pmid: 32749249 |
| [38] |
Boots JMM, Quax RAM. High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: A benefit-risk assessment[J]. Drug Saf, 2022, 45(10): 1019-1036.
doi: 10.1007/s40264-022-01216-w |
| [39] |
Rosati A, Conti P, Berto P, et al. Efficacy, safety and pharmacoeconomic analysis of intravenous ferric carboxymaltose in anemic hemodialysis patients unresponsive to ferric gluconate treatment: a multicenter retrospective study[J]. J Clin Med, 2022, 11(18):5284.
doi: 10.3390/jcm11185284 URL |
| [40] |
Hu S, Liu L, Pollock RF, et al. Intravenous iron for the treatment of iron deficiency anemia in China: A patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose[J]. J Med Econ, 2022, 25(1): 561-570.
doi: 10.1080/13696998.2022.2065092 URL |
| [41] |
Sinclair RCF, Nadaraja S, Kennedy NA, et al. Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK[J]. Sci Rep, 2022, 12(1): 18859.
doi: 10.1038/s41598-022-23581-3 pmid: 36344720 |
| [42] | Cheng HY, Frise MC, Curtis MK, et al. Intravenous iron delivers a sustained (8-week) lowering of pulmonary artery pressure during exercise in healthy older humans[J]. Physiol Rep, 2019, 7(13): e14164. |
| [43] |
Howard LS, Watson GM, Wharton J, et al. Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension[J]. Pulm Circ, 2013, 3(1): 100-107.
doi: 10.4103/2045-8932.109923 pmid: 23662181 |
| [44] |
Ferreira MB, Saraiva FA, Fonseca T, et al. Clinical associations and prognostic implications of 6-minute walk test in rheumatoid arthritis[J]. Sci Rep, 2022, 12(1): 18672.
doi: 10.1038/s41598-022-21547-z pmid: 36333405 |
| [45] |
Ghio S, Fortuni F, Capettini AC, et al. Iron deficiency in pulmonary arterial hypertension: prevalence and potential usefulness of oral supplementation[J]. Acta Cardiol, 2021, 76(2): 162-167.
doi: 10.1080/00015385.2019.1694760 URL |
| [46] |
Olsson KM, Fuge J, Brod T, et al. Oral iron supplementation with ferric maltol in patients with pulmonary hypertension[J]. Eur Respir J, 2020, 56(5):2000616.
doi: 10.1183/13993003.00616-2020 URL |
| [47] |
Viethen T, Gerhardt F, Dumitrescu D, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: A pilot study[J]. Int J Cardiol, 2014, 175(2): 233-239.
doi: 10.1016/j.ijcard.2014.04.233 pmid: 24880481 |
| [48] |
Akaslan D, Aslanger E, Ataş H, et al. The Effects of iron replacement on functional capacity in patients with group 1 and group 4 pulmonary hypertension[J]. Turk Kardiyol Dern Ars, 2022, 50(7): 492-497.
doi: 10.5543/tkda.2022.22343 pmid: 36200717 |
| [49] |
Ruiter G, Manders E, Happé CM, et al. Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency[J]. Pulm Circ, 2015, 5(3): 466-472.
doi: 10.1086/682217 pmid: 26401247 |
| [50] | Theobald V, Grünig E, Benjamin N, et al. Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?[J]. Pulm Circ, 2023, 13(2): e12242. |
| [51] |
Howard L, He J, Watson GMJ, et al. Supplementation with iron in pulmonary arterial hypertension:two randomized crossover trials[J]. Ann Am Thorac Soc, 2021, 18(6): 981-988.
doi: 10.1513/AnnalsATS.202009-1131OC pmid: 33735594 |
| [52] |
Ruiter G, Lankhorst S, Boonstra A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension[J]. Eur Respir J, 2011, 37(6): 1386-1391.
doi: 10.1183/09031936.00100510 pmid: 20884742 |
| [1] | 王沁濡, 尹琴, 李娟, 甘洪玉. 中医药治疗慢性阻塞性肺疾病合并肺动脉高压的研究进展[J]. 临床荟萃, 2024, 39(2): 188-192. |
| [2] | 安勤燕, 姜蓉, 康彬, 杜明, 周仁明, 赵洪娟, 段炜, 卢飞, 刘锦铭. 特发性肺动脉高压患者RDW、NT-ProBNP、BigET-1、HMGB1水平变化及临床意义[J]. 临床荟萃, 2021, 36(11): 1001-1004. |
| [3] | 孙明文1，何凤珍2，岳红梅1. 呼出气一氧化氮在非哮喘肺部疾病应用进展[J]. 临床荟萃, 2017, 32(9): 816-818. |
| [4] | 袁雅冬;宫小薇. 2013年呼吸病学新进展[J]. 临床荟萃, 2014, 29(3): 275-281. |
| [5] | 何小梅;赵丽娜;樊文峰;李晓静. 二尖瓣血流传播速度在室间隔缺损伴肺动脉高压患者左心室舒张功能评价中的应用[J]. 临床荟萃, 2008, 23(5): 340-341. |
| [6] | 王恩伟;邢西忠;张秀辉;邢泉生. 前列腺素E1在治疗风湿性心脏病合并肺动脉高压中的时效关系和量效关系[J]. 临床荟萃, 2004, 19(1): 14-17. |
| [7] | 刘盛辉;丁学勤;张美玉;崔京宁;孙金萍;胡建山;刘世颖;耿兰增;李菊;付天真;于石成. 锌原卟啉测定对铁缺乏症的诊断价值[J]. 临床荟萃, 2001, 16(16): 733-734. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
